Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.

[2] This drug was developed by Bristol-Myers Squibb.

Immune activation: Dostarlimab Other: Ibalizumab

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.